Skribek M, Rounis K, Afshar S, et al. - Researchers assessed the impact of the timeline and reasons for corticosteroid use on survival outcomes among patients suffering from advanced non–small cell lung cancer who were managed with immune-checkpoint inhibitors (ICIs). Patients were split into three subgroups by reason for steroid use: a) supportive reasons but not for cancer palliation; b) palliation of cancer-associated symptoms; c) treatment of immune-related adverse events (irAEs). Corticosteroids were received by 46.3% of 196 patients included in the study. Overall survival (OS) was unaffected by steroid administration because of irAEs compared to the steroid naïve group. There was no impact of the timeline of steroid administration on OS in this cohort. Seemingly, ICI efficacy is not hindered by steroids due to irAEs. However, use of high-dose steroids to palliate cancer-related symptoms might reflect the poor prognosis of these patients.